Navigation Links
Rosecrance and Chicago's Department of Environment Collaborate to Help Families Dispose of Unwanted Medicines and Drugs
Date:10/8/2007

so protect the environment," he added.

Dr. Wright also said that in families where prescription and over-the-counter drugs are being used properly, it is important for parents to keep them in a secure place and to make sure cough syrup levels aren't declining too rapidly, or that pill bottle aren't emptying too quickly.

CLEAN OUT YOUR MEDICINE CABINET DAY

Saturday, October 13th

8:00 am - 3:00 pm

Northeastern Illinois University

5500 N. St. Louis

Chicago, IL

For more information about this event or the City of Chicago's permanent Household Chemicals & Computer Recycling Facility please call 311 or visit the City's Web site at: http://www.cityofchicago.org/environment.

About Rosecrance

Rosecrance Health Network is a leading provider of inpatient and outpatient substance abuse treatment services for adolescents and adults. For more information please call 1-800-ALCOHOL or visit http://www.rosecrance.org.

CONTACT:

Lisabeth Weiner

312.252.7360 (voice)

312.485.6211 (cell)

lisweiner@lisweiner.com (email) Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Thomas Wright http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=65028


'/>"/>
SOURCE Rosecrance Health Network
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Drugs control and industry departments to share a common e-platform
2. Apollo Hospital to collaborate with US cancer center to open new radiation therapy department
3. Bird flu threat ruled out: Karnataka Forest Department
4. Fire department stem cell donors felicitated with Honor Roll of Life
5. UK Health Department White Paper aimed at improving Health care facilities
6. New York Condom To Be Promoted Soon: Health Department
7. Extravagant Pay For Emergency Department Head Of Caboolture Hospital
8. The Department of Health Gears Up To The Arrival Of JE Vaccines
9. Department of Health Encourages Women To Deliver Babies At Home
10. Health Department Geared Up To Meet Diarrhoea Cases
11. A&E departments To Be Shut Down warns NHS chief
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...cientific studies have now reported that exposure ...se the likelihood of sleep disturbance. The cause ...s those from other electrical appliances and high ...ing free radicals in the cerebrospinal fluid (CSF)...sleep-controlling hormone melatonin. , ...
(Date:1/7/2009)... time pancreatic cancer is discovered, it is often...ick Swayze) and survival rates are low. Dr. Aaron...pancreatic, liver and gastrointestinal (GI) cancer...ed a groundbreaking team approach to improve commu...r patients. , Morristow...
(Date:1/7/2009)...ural Alternatives International, Inc. ("NAI") (Nas...and marketer of customized nutritional supplements... its former President, Randell Weaver,s employment...ted certain amendments to its credit facility with...ents extend the maturity date for the working capi...
(Date:1/7/2009)...mbulatory Services of America,Inc. announced the f...h,radiation oncology joint venture. ROSA of South...r Center - Gulf Shores, P.C., Monroeville Radiatio...cology, P.C., and ASA,s,subsidiary, Radiation Onco...ama will own and operate four radiation oncology f...
Breaking Medicine News(10 mins):Health News:Welsh Laboratory Discovers Natural Antidote for Sleep Disturbance Caused by Cell Phones; Don't Disturb Me! Asphalia for Natural Sleep 2Health News:Welsh Laboratory Discovers Natural Antidote for Sleep Disturbance Caused by Cell Phones; Don't Disturb Me! Asphalia for Natural Sleep 3Health News:Nationally-Recognized Pancreatic Cancer Surgeon Develops Unique Team Approach to Improve Patient Outcomes 2Health News:Natural Alternatives International, Inc. Announces Change in Executive Officer and Loan Modification and Extension 2Health News:Ambulatory Services of America, Inc. Announces Joint Venture with Gulf Coast Cancer Centers 2
...entified a new regulatory mechanism in the process...g could open op new // approaches to the treatme...niversity of Bonn, working in collaboration with s...in, have found that mice with a particular gene de...
...he migratory route of wild birds had so far not wi...the latest news about the death of a 14-year-old b...reported only in Asia with the death toll about 70...y denies the rumors about bird flu being the cause...
...eneral practitioner and founder president of the N...Campbell is pioneer // in founding the national a...orant about the health problems involved with obes...ken many people into surprise, though there was lo...
...h it the burden of making resolutions. But how tru...ose weight and look gorgeous at the New Year’s but...when most people actually try to follow through on... a survey. According to a survey by the research ...
Other Medicine News:
(Date:1/7/2009).../ -- ImQuest Life Sciences announced today the suc...od and Drug Administration to initiate human clini...bitor IQP-0410. ImQuest anticipates initiating the...QP-0410 is a novel small molecule inhibitor of HIV...ranscriptase inhibitor (NNRTI). The compound posse...
(Date:1/6/2009)...lts from prior U.S., U.K. and China Trials , , ... Inc. (VTI), a development stage company targeting... has begun for a randomized, controlled, multi-cen...tracorporeal Liver Assist Device (ELAD) as a treat...nder three protocols. The study is open for enroll...
(Date:1/6/2009)...-USNewswire/ -- Sequella, Inc., a clinical-stage b...idemic potential, announced today that SQ109, its ...sis (TB), was the first drug approved for evaluati... Dynport Vaccine Company LLC and Quintiles Transna...itute of Allergy and Infectious Diseases (NIAID), ...
(Date:1/5/2009)...Cylene Pharmaceuticals announced today that it has...2 protein kinase inhibitor, CX-4945, in patients w... multiple myeloma. The primary endpoints of the or...ty, tolerance and PK properties of CX-4945 and to ...n addition, multiple mechanism-related pharmacodyn...
Breaking Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3Raydiance collaborates with Rutgers MTF to develop innovative tissue processing approaches 1269 1Raydiance collaborates with Rutgers MTF to develop innovative tissue processing approaches 1269 2MU study finds that sitting may increase risk of disease 1265 1MU study finds that sitting may increase risk of disease 1265 2MU study finds that sitting may increase risk of disease 1265 3New HPV vaccine under study 6618 1New HPV vaccine under study 6618 2Stress hormone may hasten the progression of certain blood cancers 6614 1Stress hormone may hasten the progression of certain blood cancers 6614 2Stress hormone may hasten the progression of certain blood cancers 6614 3
...Kinetics Profile, LAUSANNE, Switzerland, April 19,...), a global independent biopharmaceutical,developm...ditions,presented additional results of a previou...hibitor Debio 025 in HIV/HCV (hepatitis C,virus) c...e 42nd,Annual Meeting of the European Association ...
...USINESS WIRE)--Apr 19, 2007 - Abraxis BioScience,...aceutical,company, discussed results from two pre-...erapy induced angiogenesis and,rationale for combi...spension (paclitaxel protein-bound particles for i...nhibitor drugs like,bevacizumab (Avastin(R)) at th...
Other Medicine Technology:Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 2Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 3Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 2Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 3Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 5
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
Medicine Products: